“…CASE REPORT: We describe the case of a 57-year-old patient that reported SSNHL and tinnitus in his right ear 2 days after the inoculation of the Oxford-AstraZeneca (VAXZEVRIA) Covid-19 vaccine. The patient almost fully recovered after therapy and was referred to a long term follow-up program. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We report a case of a young woman who presented with VITT and cerebral CVST 7 days following vaccination with ChAdOx1 nCov-19 (AstraZeneca). While the initial MRI was considered void of pathological findings, MRI 3 days later revealed extensive CVST of the transversal and sigmoidal sinus with intracerebral haemorrhage. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Administration of AstraZeneca/Oxford and Johnson & Johnson/Janssen Covid-19 vaccines which use an adenovirus vector for DNA delivery has been associated with very rare thromboembolic complications coupled with an immune response to platelet factor 4 protein. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The findings confirm that Oxford/AstraZeneca is the top vaccine used across the globe with 26.54%, the United States is the top in vaccination, with 277,290,173, India is the top in number of daily vaccinations with 3.659357M, and in total vaccinations per hundred people, the United States has the highest count with 82.91, among the top five countries. …”
Enlace del recurso
Enlace del recurso

“…Inoculated vaccines were ChAdOx1 (AstraZeneca/Oxford), BNT162b2 (Pfizer/BioNTech), JNJ-78436735 (Janssen), and mRNA-1273 (Moderna). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Pfizer-BioNTech had 20.8% (95% CI 11.6%–29.0%) vaccine effectiveness (VE) against infection after 1 dose and 70.0% (95% CI 65.3%–74.1%) after 2 doses, Moderna had 52.8% (95% CI 30.7%–67.8%) VE after 1 dose and 70.3% (95% CI 52.2%–81.5%) after 2 doses, and Oxford-AstraZeneca had 40.3% (95% CI 31.8%–47.7%) VE after 1 dose. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Guillain-Barré syndrome, an acute inflammatory neuropathy well recognised as a rare complication of influenza vaccination, has been reported to follow administration of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine. METHODS: We report four patients with inflammatory demyelinating polyneuropathy after vaccination in whom a relapsing or progressive course indicated the development of chronic inflammatory demyelinating polyneuropathy (CIDP). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The study also considered the impact of Pfizer-BioNTech (BNT162b2), AstraZeneca (ChAd0x1), and Moderna (mRNA-1273) on Beta (B.1.1.7) and Delta (B.1.617.2) viral variants and the impact of administering booster doses given the evolution of viral variants of the virus.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Among vaccines designed to prevent COVID-19, there are those adenoviral vector-based, such as Vaxzevria® (formerly COVID-19 Vaccine AstraZeneca). The product insert states that it can cause very rare coagulation disorders, in particular thrombosis with thrombocytopenia syndrome in some cases accompanied by bleeding, cerebrovascular venous or sinus thrombosis, and thrombocytopenia, including immune thrombocytopenia, also associated with bleeding. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The most used products were mRNA vaccines, followed by Vaxzevria-AstraZeneca and Jcovden-Janssen/Johnson & Johnson. All countries established criteria to define categories of individuals to be vaccinated as a priority. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Approximately 82% and 18% of the participants received Pfizer–BioNTech and Oxford–AstraZeneca vaccines, respectively, and nearly 71% received two doses of the vaccine. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This work identifies the innovations that made it possible for the Bio-Manguinhos/Fiocruz Immunobiological Technology Institute to engage in the entire production of the Oxford/AstraZeneca vaccine (ChAdOx1 nCov-19) in Brazil, just 1.8 years after the COVID-19 pandemic was declared. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The capability of the proposed vaccine supply chain model is illustrated using a real-world case study on vaccination against SARS-CoV-2 in the UK that concerns both viral vectors (e.g., AZD1222 developed by Oxford-AstraZeneca) and RNA-based vaccine (e.g., BNT162b2 developed by Pfizer-BioNTech). …”
Enlace del recurso
Enlace del recurso

“…In total, 532 cases of myocarditis after COVID-19 vaccination were reported (462, 86.8% men and 70, 13.2% women, age range 12 to 80) with the following distribution: Pfizer-BioNTech: 367 (69%), Moderna: 137 (25.8%), AstraZeneca: 12 (2.3%), Janssen/Johnson & Johnson: 6 (1.1%), COVAXIN: 1 (0.1%), and unknown mRNA vaccine: 9 (1.7%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: An online questionnaire-based study was performed among the recipients of COVID-19 vaccines RESULTS: Majority (73.6%) of the responders had received the Covishield vaccine (AstraZeneca-Oxford), while 26.4% had been vaccinated with Covaxin (Bharat Biotech-ICMR). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…More ITP events were triggered by mRNA vaccines (BNT162b2 (n = 29) > mRNA-1273 (n = 13)) than with adenoviral vaccines (ChAdOx1-S AstraZeneca (n = 15) > Ad26.COV2-S (n = 9)). Most of the patients were treated with steroids or IVIG, or both. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…It can be assumed that the issues surrounding the AstraZeneca vaccine, which occurred at the start of the vaccination campaign, may have led to an increase in people’s hesitancy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Vascular events occurred more with the Pfizer and AstraZeneca vaccines (81.6%), and mostly presented unilaterally (73.8%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…He developed allograft nephropathy after receiving the AstraZeneca COVID-19 vaccine 16 months ago and lost the second graft as a result. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A combination of tixagevimab and cilgavimab (Evusheld [AstraZeneca Cambridge, United Kingdom]) was granted emergency use authorization for preexposure prophylaxis at the end of 2021, but questions remained regarding how this would be tolerated and the side effects associated with its use. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso